- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.07. | P3 Health Partners beruft CEO Aric Coffman nach Rücktritt in den Verwaltungsrat | 1 | Investing.com Deutsch | ||
| 09.07. | P3 Health Partners Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.06. | P3 Health Partners Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.05. | P3 Health shares dip as TD Cowen cuts price target to $8 | 1 | Investing.com | ||
| 28.05. | P3 Health-Aktien fallen - TD Cowen Kursziel auf 8 US-Dollar senkt | 2 | Investing.com Deutsch | ||
| P3 HEALTH PARTNERS Aktie jetzt für 0€ handeln | |||||
| 16.05. | P3 Health Partners reaffirms $130M EBITDA improvement plan as operational initiatives accelerate in 2025 | 1 | Seeking Alpha | ||
| 15.05. | P3 Health Partners GAAP EPS of -$6.28 beats by $1.64, revenue of $373.2M beats by $11.13M | 1 | Seeking Alpha | ||
| 14.05. | What to Expect from P3 Health Partners' Earnings | 1 | Benzinga.com | ||
| 04.04. | P3 Health Partners Announces 1-for-50 Reverse Stock Split | - | Investing.com | ||
| 04.04. | P3 Health Partners Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.04. | P3 Health Partners Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 28.03. | P3 Health stock neutral rating reiterated after earnings miss | 2 | Investing.com | ||
| 28.03. | P3 Health Partners targets profitability in 2025 with adjusted EBITDA guidance of up to $5M | 1 | Seeking Alpha | ||
| 13.02. | P3 Health Partners strebt Profitabilität bis 2025 mit Umsatz von bis zu 1,5 Milliarden US-Dollar an | 11 | Investing.com Deutsch | ||
| 13.02. | P3 Health Partners Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11.24 | P3 Health Partners Announces Third Quarter 2024 Results | 209 | Business Wire | HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its... ► Artikel lesen | |
| 07.08.24 | P3 Health Partners Announces Second Quarter 2024 Results | 154 | Business Wire | HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,104 | +0,97 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes | LONDON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics ("Sernova") (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) today announced a Collaborative Research Agreement with Eledon Pharmaceuticals... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,720 | -0,55 % | Atossa Therapeutics, Inc.: Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22 | SEATTLE, WASHINGTON / ACCESS Newswire / May 20, 2025 / Atossa Therapeutics, Inc. (Nasdaq:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines... ► Artikel lesen | |
| PING AN HEALTHCARE | 1,046 | -1,46 % | Ping An Healthcare and Technology Company Limited: Ping An Good Doctor Revamps Brand and Launches Annual Healthcare Service Brand | HONG KONG and SHANGHAI, June 11, 2025 /PRNewswire/ -- The Ping An Good Doctor Brand Revamp & Ping An Healthcare Services Brand Launch Conference was held in Shanghai. Ping An Healthcare and... ► Artikel lesen | |
| CO-DIAGNOSTICS | 0,220 | +1,85 % | Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results | SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the... ► Artikel lesen | |
| CYTOSORBENTS | 0,921 | +4,42 % | Cytosorbents Corp: CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR | PRINCETON, N.J., July 2, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions... ► Artikel lesen | |
| VERU | 0,522 | +1,16 % | Veru Inc.: Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation | --During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China | Builds on clearances already received by FDA and EMAChina has the largest population of patients with hepatocellular carcinoma in the world BRISBANE, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Tempest... ► Artikel lesen | |
| VOLITIONRX | 0,680 | 0,00 % | VolitionRx - Nu.Q advances in lung cancer management | Despite rapid advancements in cancer treatments, effective diagnostics for early screening and disease monitoring continue to be an unmet need. This is felt acutely in lung cancer, which is the leading... ► Artikel lesen | |
| EKSO BIONICS | 3,790 | 0,00 % | Ekso Bionics Holdings, Inc.: Virtual eksoUniversity to Support Continuing Education of PTs and PTAs Across the Country | ||
| IMUNON | 0,470 | 0,00 % | Imunon, Inc.: IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan | Management provides Nasdaq Hearing Panel with a comprehensive executable plan for long term compliance LAWRENCEVILLE, N.J., July 15, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage... ► Artikel lesen | |
| BEYOND AIR | 2,500 | 0,00 % | XFRA 48L0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBEYOND AIR INC.... ► Artikel lesen | |
| AVINGER | 0,465 | -22,17 % | NSE - Avinger Inc - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| NOVACYT | 0,466 | -0,11 % | Novacyt S.A. - Launch of LightBench® Discover | ||
| AROVELLA THERAPEUTICS | 0,071 | +29,36 % | AROVELLA THERAPEUTICS LIMITED: Notification regarding unquoted securities - ALA | ||
| PROCEPT BIOROBOTICS | 58,34 | 0,00 % | Procept BioRobotics: BofA bestätigt Kaufempfehlung trotz geplanter Medicare-Kürzungen |
P3 HEALTH PARTNERS INC gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 6,470 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu P3 HEALTH PARTNERS INC finden Sie auf Wallstreet Online.